Last reviewed 2026-05-30 · How we verify

VPI-2690B medium dose

Vascular Pharmaceuticals, Inc. · Phase 2 active Small molecule ✓ Verified May 2026

VPI-2690B medium dose is a Small molecule drug developed by Vascular Pharmaceuticals, Inc.. It is currently in Phase 2 development.

VPI-2690B is a treatment being studied in a Phase 2 clinical trial for Diabetic Nephropathy. The medium dose of VPI-2690B is being compared to a placebo in this trial, but the exact mechanism of action is unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VPI-2690B medium dose
Sponsor	Vascular Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VPI-2690B medium dose CI brief — competitive landscape report
VPI-2690B medium dose updates RSS · CI watch RSS
Vascular Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about VPI-2690B medium dose

What is VPI-2690B medium dose?

VPI-2690B medium dose is a Small molecule drug developed by Vascular Pharmaceuticals, Inc..

Who makes VPI-2690B medium dose?

VPI-2690B medium dose is developed by Vascular Pharmaceuticals, Inc. (see full Vascular Pharmaceuticals, Inc. pipeline at /company/vascular-pharmaceuticals-inc).

What development phase is VPI-2690B medium dose in?

VPI-2690B medium dose is in Phase 2.

Manufacturer: Vascular Pharmaceuticals, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing